Clinicians and laboratories are faced with increasing challenges in managing workload and patient needs when it comes to reproductive health. Staggering costs to the U.S. healthcare system caused by the growing number of new infections demand action in the way we test for sexually-transmitted infections (STIs).1 For vaginal infections, traditional diagnostics leave up to 40% of women with vaginitis undiagnosed after an initial clinical visit.2
The BD MAX™ Women’s Health and STI portfolio is focused on providing accurate, reliable results–enabling clinicians and labs to elevate patient care.
Vulvovaginal complaints are one of the most common reasons for women to seek medical advice.3 Learn More>>
Testing simultaneously for Chlamydia trachomatis (CT), Neisseria gonorrhea (GC) and Trichomonas vaginalis (TV) is optimal for detection of the most common treatable STIs in female patients.4 Learn More>>
Group B streptococcal disease (GBS) is the leading infectious cause of morbidity and mortality among infants in the United States.5 Learn More>>